Phathom Pharmaceuticals (PHAT) Offers Eligible Patients VOQUEZNA for as Little as $0
Phathom Pharmaceuticals (PHAT) announced that eligible patients may pay as little as $0 for VOQUEZNA tablets through BlinkRx, with free home delivery and prior authorization support. The program is subject to eligibility requirements and benefit limits. Cash-pay options start at $55 per 30-day supply, with state-specific discounts in Massachusetts. No financial impact or revenue estimates were provided.
How this was made

The 30-second read
Why it matters
The announcement provides a new pricing pathway but lacks quantitative guidance, making the immediate market impact uncertain.
Market read
A modest, low‑impact commercial initiative that may slightly improve prescription rates without clear revenue implications.
What to watch
Potential administrative costs of the program and insurer reimbursement policies.
Background
Phathom Pharmaceuticals (PHAT) markets VOQUEZNA for gastro‑esophageal reflux disease (GERD). The company introduced a patient‑access program offering the drug at $0 for eligible insured patients, with a cash‑pay option for uninsured patients.
Ticker impact
Phathom Pharmaceuticals announced a program allowing eligible commercially insured patients to obtain VOQUEZNA at $0 out‑of‑pocket, a new commercial access initiative.
potential slight upside as cost barrier is removed, but limited by unknown uptake.
Lower out‑of‑pocket cost may encourage prescriptions, yet no financial guidance or volume estimates are provided.
Market effects
May marginally improve outlook for GERD treatment segment.
Limited to U.S. commercial insurance market.
Low; impact confined to Phathom and its patients.
Counterpoint
Without clear uptake data, the program may not translate into meaningful sales.
Key entities
- companyPhathom Pharmaceuticals
U.S. biotech developing VOQUEZNA for GERD.



